UnitedHealth Group Incorporated (UNH) Stock Analysis
UnitedHealth’s Q3 margin rebound, integrated Optum platform, and discounted 18.5x forward P/E support a recovery thesis, though Medicare policy, medical-cost execution, and antitrust scrutiny remain substantial risks.
Overview
UnitedHealth Group combines UnitedHealthcare’s commercial and government health coverage with Optum’s care delivery, pharmacy-benefit management, and healthcare technology businesses. This vertical integration provides scale, data advantages, customer switching costs, and opportunities to manage costs across the care continuum. The company generated $447.6 billion of FY2025 revenue, up 12%, and reported Q3 2026 revenue of $112.7 billion, down 0.4% year over year but 1.2% above consensus. The quarter showed a substantial operational rebound: adjusted EPS was $4.69 versus $4.14 expected, operating margin expanded to 5.8% from 3.8%, and MCR improved to 88.4%; excluding a $610 million reserve release, core MCR was 89.1%. Management raised FY2026 adjusted EPS guidance to at least $20.50. **The recovery thesis depends on disciplined repricing and continued medical-cost control**, while Optum Health works toward 6%–8% margins by 2028. At about $380, shares trade at 18.5x FY2026 adjusted EPS, below the historical 20x–22x range. The report’s probability-weighted FY2031 target is $687.95, with Medicare enrollment outcomes, FY2027 guidance, and margin recovery as key catalysts and policy and antitrust exposure as major risks.